Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 79

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The causes and consequences of pituitary gigantism

Beckers, Albert, Petrossians, Patrick, Hanson, Julien, Daly, Adrian F. · 2018 · Nature Reviews Endocrinology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-018-0114-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 195

  1. Jelenkovic, A. et al. Genetic and environmental influences on height from infancy to early adulthood: an individual-based pooled analysis of 45 twin cohorts. Sci. Rep. 6, 28496 (2016). · DOI · Paper page
  2. Macé, A. et al. CNV-association meta-analysis in 191,161 European adults reveals new loci associated with anthropometric traits. Nat. Commun. 8, 744 (2017). This complex analysis shows the importance of CNV as well as mutation on human height. · DOI
  3. Zong, X.-N., Li, H., Wu, H.-H. & Zhang, Y.-Q. Socioeconomic development and secular trend in height in China. Econ. Hum. Biol. 19, 258–264 (2015). · DOI
  4. Fudvoye, J. & Parent, A.-S. Secular trends in growth. Ann. Endocrinol. (Paris). 78, 88–91 (2017). · DOI
  5. Hermanussen, M. et al. Growth variation, final height and secular trend. Proceedings of the 17th Aschauer Soiree, 7th November 2009. HOMO 61, 277–284 (2010). · DOI
  6. Judge, T. A. & Cable, D. M. The effect of physical height on workplace success and income: preliminary test of a theoretical model. J. Appl. Physchol. 89, 428–441 (2004).
  7. Deaton, A. S., Hall, W. & School, W. W. Life at the top: the benefits of height. Econ. Hum. Biol. 7, 133–136 (2009). · DOI · Paper page
  8. Lee, J. M. & Howell, J. D. Tall girls: the social shaping of a medical therapy. Arch. Pediatr. Adolesc. Med. 160, 1035–1039 (2006). · doi:10.1001/archpedi.160.10.1035
  9. Rayner, J.-A., Pyett, P. & Astbury, J. The medicalisation of ‘tall’ girls: a discourse analysis of medical literature on the use of synthetic oestrogen to reduce female height. Soc. Sci. Med. 71, 1076–1083 (2010). · DOI
  10. Hannema, S. E. & Sävendahl, L. Clinical practice the evaluation and management of tall stature. Horm. Res. Paediatr. 85, 347–352 (2016). · DOI
  11. Davies, J. H. & Cheetham, T. Investigation and management of tall stature. Arch. Dis. Child 99, 772–777 (2014). This article provides a concise and practical overview of the clinical assessment and management of tall stature. · DOI
  12. Stalman, S. E., Pons, A., Wit, J. M., Kamp, G. A. & Plötz, F. B. Diagnostic work-up and follow-up in children with tall stature: a simplified algorithm for clinical practice. J. Clin. Res. Pediatr. Endocrinol. 7, 260–267 (2015). · doi:10.4274/jcrpe.2220
  13. Coutant, R., Donzeau, A., Decrequy, A., Louvigné, M. & Bouhours-Nouet, N. How to investigate a child with excessive growth? Ann. Endocrinol. (Paris). 78, 98–103 (2017). · doi:10.1016/j.ando.2017.04.006
  14. Baron, J. et al. Short and tall stature: a new paradigm emerges. Nat. Rev. Endocrinol. 11, 735–746 (2015). This paper is an excellent overview of the past findings and future directions of human height research. · DOI · Paper page
  15. Jee, Y. H., Andrade, A. C., Baron, J. & Nilsson, O. Genetics of short stature. Endocrinol. Metab. Clin. North Am. 46, 259–281 (2017). · DOI
  16. Committee on Genetics. Health supervision children with Marfan syndrome. Pediatrics 132, e1059–e1072 (2013). · DOI
  17. Verge, C. F. & Mowat, D. Overgrowth. Arch. Dis. Child. 95, 458–463 (2010). · doi:10.1136/adc.2009.157693
  18. Barstow, C. & Rerucha, C. Evaluation of short and tall stature in children. Am. Fam. Physician 92, 43–50 (2015).
  19. Meazza, C., Gertosio, C., Giacchero, R., Pagani, S. & Bozzola, M. Tall stature: a difficult diagnosis? Ital. J. Pediatr. 43, 66 (2017). · doi:10.1186/s13052-017-0385-5
  20. Albuquerque, E. V. A., Scalco, R. C. & Jorge, A. A. L. MANAGEMENT OF ENDOCRINE DISEASE: diagnostic and therapeutic approach of tall stature. Eur. J. Endocrinol. 176, R339–R353 (2017). · DOI
  21. Stratakis, C. A. A giant? Think of genetics: growth hormone-producing adenomas in the young are almost always the result of genetic defects. Endocrine 50, 272–275 (2015). · doi:10.1007/s12020-015-0645-3
  22. Rostomyan, L. et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr. Relat. Cancer 22, 745–757 (2015). This article presents the first international study using standardized data collection to assess the characteristics of pituitary gigantism. · DOI · Paper page
  23. Rostomyan, L., Daly, A. F. & Beckers, A. Pituitary gigantism: causes and clinical characteristics. Ann. Endocrinol. (Paris). 76, 643–649 (2015). · doi:10.1016/j.ando.2015.10.002
  24. de Herder, W. W. [Giantism. A historical and medical view]. Ned Tijdschr. Geneeskd 148, 2585–2590 (2004).
  25. de Herder, W. W. Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). Pituitary 12, 236–244 (2009). This paper provides expert historical background of the medical study of gigantism and acromegaly. · DOI
  26. Marie, P. Sur deux cas d’acromegalie. Hypertrophe singuliere no congénitale des extréméties supérieures, inférieures et cephalique [French]. Révue Méd. Française 6, 297–333 (1886).
  27. de Herder, W. W. A postcard of a giant and his physician (collection de Herder, W. W.). J. Endocrinol. Invest. 28, 392 (2005). · doi:10.1007/bf03347211
  28. Dana, C. L. Giants and gigantism. Scribner’ Mag. 17, 179–185 (1895).
  29. Dufrane, A., Launois, P. E. & Roy, P. Les Relations du Gigantisme et L’acromegalie Expliquees par L’autopsie du Géant Constantin (Masson, Paris, 1903).
  30. Cushing, H. The Pituitary Body and Its Disorders (J. B. Lippincott Company, 1912).
  31. Beclère, A. Le traitement medical des tumeurs hypophysaires, du gigantisme et de I’acromégalie par la radiothérapie [French]. Arch. d’Electricité Méd. Exp. Clin. 17, 163–180 (1909).
  32. Melmed, S. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013). · DOI · Paper page
  33. Katznelson, L. et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014). · DOI · Paper page
  34. Petrossians, P. et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer 24, 505–518 (2017). · DOI · Paper page
  35. Beckers, A. et al. X-Linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr. Relat. Cancer 22, 353–367 (2015). This article presents a detailed assessment of the unique clinical features of X-LAG syndrome. · DOI · Paper page
  36. Trivellin, G. et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N. Engl. J. Med. 371, 2363–2374 (2014). This publication presents the discovery and description of X-LAG syndrome. · DOI · Paper page
  37. Beckers, A., Aaltonen, L. A., Daly, A. F. & Karhu, A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr. Rev. 34, (239–277 (2013).
  38. Daly, A. F. & Beckers, A. Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinol. Metab. Clin. North Am. 44, (19–25 (2015).
  39. Martucci, F., Trivellin, G. & Korbonits, M. Familial isolated pituitary adenomas: an emerging clinical entity. J. Endocrinol. Invest. 35, 1003–1014 (2012). · DOI
  40. Hannah-Shmouni, F., Trivellin, G. & Stratakis, C. A. Genetics of gigantism and acromegaly. Growth Horm. IGF Res. 30–31, 37–41 (2016). · doi:10.1016/j.ghir.2016.08.002
  41. Daly, A. F. et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab. 91, 3316–3323 (2006). This article presents the initial clinical description and definition of FIPAs, the most frequently encountered familial pituitary adenoma presentation. · doi:10.1210/jc.2005-2671
  42. Daly, A. F. et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab. 95, E373–E383 (2010). This large cohort study establishes the significant differences in disease characteristics and therapeutic responses between acromegaly and gigantism due to AIP mutations versus non-mutated cases. · DOI · Paper page
  43. Hernández-Ramírez, L. C. et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J. Clin. Endocrinol. Metab. 100, E1242–E1254 (2015). This paper provides an in-depth analysis of the role of AIP mutations in sporadic and familial pituitary adenoma. · DOI · Paper page
  44. Trivellin, G. & Korbonits, M. AIP and its interacting partners. J. Endocrinol. 210, 137–155 (2011). · DOI
  45. Chahal, H. S. et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J. Clin. Endocrinol. Metab. 97, 1–10 (2012). · DOI
  46. Bolger, G. B. et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 278, 33351–33363 (2003). · DOI · Paper page
  47. Ritvonen, E. et al. Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur. J. Endocrinol. 176, 243–252 (2017). · doi:10.1530/eje-16-0620
  48. Tuominen, I. et al. AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling. Oncogene 34, 1174–1184 (2015). · DOI
  49. de Oliveira, S. K. & Smolenski, A. Phosphodiesterases link the aryl hydrocarbon receptor complex to cyclic nucleotide signaling. Biochem. Pharmacol. 77, 723–733 (2009). · DOI
  50. Linnert, M. et al. The FKBP-type domain of the human aryl hydrocarbon receptor-interacting protein reveals an unusual Hsp90 interaction. Biochemistry 52, 2097–2107 (2013). · DOI
  51. Formosa, R., Xuereb-Anastasi, A. & Vassallo, J. AIP regulates cAMP signalling and growth hormone secretion in GH3 cells. Endocr. Relat. Cancer 20, 495–505 (2013). · DOI
  52. Lecoq, A.-L. et al. AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocr. Relat. Cancer 23, 433–443 (2016). · DOI
  53. Hernández-Ramírez, L. C. et al. Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. Oncotarget 9, 9177–9198 (2018). · DOI
  54. Hernández-Ramírez, L. C. et al. Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J. Clin. Endocrinol. Metab. 101, 3144–3154 (2016). · DOI
  55. Morgan, R. M. L. et al. Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition. PLOS ONE 7, e53339 (2012).
  56. Formosa, R. & Vassallo, J. Aryl hydrocarbon receptor–interacting protein (AIP) N-terminus gene mutations identified in pituitary adenoma patients alter protein stability and function. Horm. Cancer 8, (174–184 (2017).
  57. Cannavo, S. et al. Increased prevalence of acromegaly in a highly polluted area. Eur. J. Endocrinol. 163, 509–513 (2010). · doi:10.1530/eje-10-0465
  58. Cannavo, S. et al. Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas. J. Clin. Endocrinol. Metab. 101, (1872–1879 (2016).
  59. Cannavo, S., Trimarchi, F. & Ferraù, F. Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden. Mol. Cell. Endocrinol. 457, 81–88 (2017). · DOI
  60. Lin, B. C. et al. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J. Biol. Chem. 282, 35924–35932 (2007). · DOI
  61. Raitila, A. et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am. J. Pathol. 177, (1969–1976 (2010).
  62. Lecoq, A.-L. et al. Mild pituitary phenotype in 3- and 12-month-old Aip-deficient male mice. J. Endocrinol. 231, 59–69 (2016). · DOI
  63. Gillam, M. P. et al. Somatotroph-specific aip-deficient mice display pretumorigenic alterations in cell-cycle signaling. J. Endocr. Soc. 1, 78–95 (2017). · DOI
  64. Villa, C. et al. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. Endocr. Relat. Cancer 18, 347–356 (2011). · DOI
  65. Vierimaa, O. et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312, 1228–1230 (2006). This study describes the discovery of AIP mutations as an inherited cause of pituitary adenomas. · DOI · Paper page
  66. Nagata, Y. et al. Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes. Pituitary 21, 1–9 (2018). · doi:10.1007/s11102-017-0836-4
  67. Naves, L. A. et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur. J. Endocrinol. 157, 383–391 (2007). · DOI
  68. Georgitsi, M. et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl Acad. Sci. USA 104, 4101–4105 (2007). · DOI
  69. Tichomirowa, M. A. et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur. J. Endocrinol. 165, 509–515 (2011). · DOI · Paper page
  70. Daly, A. F. et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 92, 1891–1896 (2007). · DOI · Paper page
  71. Cuny, T. et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur. J. Endocrinol. 168, 533–541 (2013). · doi:10.1530/eje-12-0763
  72. Stratakis, C. A. et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin. Genet. 78, 457–463 (2010). · DOI · Paper page
  73. Williams, F. et al. Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. J. Clin. Endocrinol. Metab. 99, 1122–1131 (2014).
  74. Igreja, S. et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum. Mutat. 31, 950–960 (2010).
  75. Leontiou, C. A. et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 93, 2390–2401 (2008). · DOI · Paper page
  76. Salvatori, R., Daly, A. F., Quinones-Hinojosa, A., Thiry, A. & Beckers, A. A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma. Endocrinol. Diabetes Metab. Case Rep. 2014, 140048 (2014).
  77. Jaffrain-Rea, M.-L. et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer 16, 1029–1043 (2009). · DOI
  78. Jaffrain-Rea, M.-L. et al. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr. Relat. Cancer 20, 753–766 (2013). · DOI
  79. Kasuki, L. et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr. Relat. Cancer 19, L25–L29 (2012). · doi:10.1530/erc-12-0020
  80. Kasuki Jomori de Pinho, L. et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94, 39–48 (2011). · doi:10.1159/000322787
  81. Imran, S. A. et al. Unusual AIP mutation and phenocopy in the family of a young patient with acromegalic gigantism. Endocrinol. Diabetes Metab. Case Rep. https://doi.org/10.1530/EDM-17-0092 (2018). · doi:10.1530/edm-17-0092
  82. Salvatori, R. et al. In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. Eur. J. Endocrinol. 177, 257–266 (2017). · DOI
  83. Radian, S. et al. Increased population risk of AIP-related acromegaly and gigantism in Ireland. Hum. Mutat. 38, 78–85 (2017). · DOI
  84. de Herder, W. W. et al. Acromegalic gigantism, physicians and body snatching. Past or present? Pituitary 15, 312–318 (2012). · DOI
  85. Vasilev, V. et al. MANAGEMENT OF ENDOCRINE DISEASE: pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis. Eur. J. Endocrinol. 175, R171–R184 (2016). · DOI
  86. Ezzat, S. et al. The prevalence of pituitary adenomas: a systematic review. Cancer 101, 613–619 (2004). · DOI · Paper page
  87. Rodd, C. et al. Somatic GPR101 duplication causing X-linked acrogigantism (XLAG) - diagnosis and management. J. Clin. Endocrinol. Metab. 101, 1927–1930 (2016). · doi:10.1210/jc.2015-4366
  88. Naves, L. A. et al. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine 51, 236–244 (2016). · DOI
  89. Daly, A. F. et al. Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocr. Relat. Cancer 23, 221–233 (2016). This study describes how X-LAG syndrome can be caused by mosaicism for chromosome Xq26.3 duplications and can be detected in the screening of patient cohorts using digital PCR. · DOI
  90. Daly, A. F. et al. GHRH excess and blockade in X-LAG syndrome. Endocr. Relat. Cancer 23, 161–170 (2016). · doi:10.1530/erc-15-0478
  91. Trivellin, G., Hernández-Ramírez, L. C., Swan, J. & Stratakis, C. A. An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: molecular biology and clinical correlations. Best Pract. Res. Clin. Endocrinol. Metab. 32, 125–140 (2018). · DOI
  92. Iacovazzo, D. et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol. Commun. 4, 56 (2016). · doi:10.1186/s40478-016-0328-1
  93. Gordon, R. J. et al. Childhood acromegaly due to X-linked acrogigantism: long term follow-up. Pituitary 19, 560–564 (2016). · doi:10.1007/s11102-016-0743-0
  94. Beckers, A. et al. Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism. Endocr. Relat. Cancer 24, L17–L20 (2017). · DOI
  95. Beckers, A., Rostomyan, L., Potorac, I., Beckers, P. & Daly, A. F. X-LAG: how did they grow so tall? Ann. Endocrinol. (Paris) 78, 131–136 (2017). · doi:10.1016/j.ando.2017.04.013
  96. Trivellin, G. et al. Characterization of GPR101 transcript structure and expression patterns. J. Mol. Endocrinol. 57, 97–111 (2016). · DOI
  97. Castinetti, F. et al. GPR101 mutations are not a frequent cause of congenital isolated growth hormone deficiency. Horm. Metab. Res. 48, 389–393 (2016). · doi:10.1055/s-0042-100733
  98. Kamenický, P., Bouligand, J. & Chanson, P. Gigantism, acromegaly, and GPR101 mutations. N. Engl. J. Med. 372, 1264–1265 (2015). · doi:10.1056/nejmc1500340
  99. Ferraù, F. et al. Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine 54, 762–767 (2016). · doi:10.1007/s12020-016-0862-4
  100. Daly, A. F., Trivellin, G. & Stratakis, C. A. Gigantism, acromegaly, and GPR101 mutations. N. Engl. J. Med. 372, 1265 (2015).
  101. Trivellin, G. et al. Screening for GPR101 defects in pediatric pituitary corticotropinomas. Endocr. Relat. Cancer 23, 357–365 (2016). · doi:10.1530/erc-16-0091
  102. Brandi, M. L. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658–5671 (2001). · DOI · Paper page
  103. Thakker, R. V. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012). · DOI · Paper page
  104. Beckers, A., Betea, D., Valdes Socin, H. & Stevenaert, A. The treatment of sporadic versus MEN1-related pituitary adenomas. J. Intern. Med. 253, 599–605 (2003). · DOI
  105. Daly, A. F. & Beckers, A. in The Pituitary 4th edn (ed. Melmed, S.) 619–630 (Elsevier, 2017).
  106. Trouillas, J. et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am. J. Surg. Pathol. 32, 534–543 (2008). · doi:10.1097/pas.0b013e31815ade45
  107. Sergeant, C. et al. Transdifferentiation of neuroendocrine cells: gangliocytoma associated with two pituitary adenomas of different lineage in MEN1. Am. J. Surg. Pathol. 41, 849–853 (2017). · doi:10.1097/pas.0000000000000803
  108. Magri, F. et al. Prevalence of double pituitary adenomas in a surgical series: clinical, histological and genetic features. J. Endocrinol. Invest. 33, 325–331 (2010). · doi:10.1007/bf03346594
  109. Vergès, B. et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 87, 457–465 (2002). · DOI · Paper page
  110. Syro, L. V. et al. Pituitary tumors in patients with MEN1 syndrome. Clinics (Sao Paulo) 67 (Suppl. 1), 43–48 (2012). · doi:10.6061/clinics/2012(sup01)09
  111. Stratakis, C. A. et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 85, 4776–4780 (2000).
  112. de Laat, J. M. et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the Dutch MEN1 study group (DMSG). J. Clin. Endocrinol. Metab. 100, 3288–3296 (2015). This long-term cohort study of pituitary disease in MEN1 discusses the challenges of a modern screening programme. · DOI · Paper page
  113. Huang, W. & Molitch, M. E. Management of nonfunctioning pituitary adenomas (NFAs): observation. Pituitary 21, 162–167 (2018). · DOI
  114. Albright, F., Butler, A. M., Hampton, A. O. & Smith, P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N. Engl. J. Med. 216, 727–746 (1937). · DOI
  115. McCune, D. J. & Bruch, H. Osteodystrophia fibrosa. Am. J. Dis. Child. 54, 806 (1937). · doi:10.1001/archpedi.1937.01980040110009
  116. Weinstein, L. S. et al. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N. Engl. J. Med. 325, 1688–1695 (1991). This study demonstrates that MAS is a Gα s -related disease. · DOI · Paper page
  117. Schwindinger, W. F., Francomano, C. A. & Levine, M. A. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc. Natl Acad. Sci. USA 89, 5152–5156 (1992). · DOI · Paper page
  118. Dumitrescu, C. E. & Collins, M. T. McCune-Albright syndrome. Orphanet J. Rare Dis. 3, 12 (2008). This paper presents a comprehensive overview of the clinical presentation and pathology of MAS. · DOI · Paper page
  119. Zacharin, M. et al. Gastrointestinal polyps in McCune Albright syndrome. J. Med. Genet. 48, 458–461 (2011). · DOI
  120. Wood, L. D. et al. Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Arch. 470, 391–400 (2017). · DOI
  121. Vasilev, V. et al. McCune-Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient. J. Clin. Endocrinol. Metab. 99, E2029–E2038 (2014). · DOI
  122. Gaujoux, S. et al. Hepatobiliary and pancreatic neoplasms in patients with McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 99, E97–E101 (2014). · DOI
  123. Salenave, S., Boyce, A. M., Collins, M. T. & Chanson, P. Acromegaly and McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 99, 1955–1969 (2014). · doi:10.1210/jc.2013-3826
  124. Akintoye, S. O. et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 87, 5104–5112 (2002). · DOI
  125. Vortmeyer, A. O. et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 97, 2404–2413 (2012). · doi:10.1210/jc.2012-1274
  126. Schwindinger, W. F., Francomano, C. A., Levine, M. A. & McKusick, V. A. DNA light on the Tegernsee giant. Lancet 338, 1454–1455 (1991). · doi:10.1016/0140-6736(91)92752-n
  127. Vogl, T. J., Nerlich, A., Dresel, S. H. & Bergman, C. CT of the “Tegernsee Giant”: juvenile gigantism and polyostotic fibrous dysplasia. J. Comput. Assist. Tomogr. 18, 319–322 (1994). · doi:10.1097/00004728-199403000-00033
  128. Dötsch, J. et al. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 81, 3839–3842 (1996).
  129. Queirolo, S. et al. Gigantism with pituitary macroadenoma: an unusual variant of McCune-Albright syndrome. J. Pediatr. Endocrinol. Metab. 22, 177–179 (2009). · doi:10.1515/jpem.2009.22.2.177
  130. Nakagawa, H. et al. Gigantism associated with McCune-Albright’s syndrome. Horm. Metab. Res. 17, 522–527 (1985). · doi:10.1055/s-2007-1013594
  131. Schoof, E. et al. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism-effect of octreotide therapy. Horm. Res. 61, 184–189 (2004).
  132. Lee, J. S. et al. Clinical guidelines for the management of craniofacial fibrous dysplasia. Orphanet J. Rare Dis. 7 (Suppl. 1), S2 (2012).
  133. Boyce, A. M. et al. Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess. J. Clin. Endocrinol. Metab. 98, E126–E134 (2013). · doi:10.1210/jc.2012-2111
  134. Collins, M. T., Singer, F. R. & Eugster, E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J. Rare Dis. 7 (Suppl. 1), S4 (2012).
  135. Belsuzarri, T. B. et al. McCune-Albright syndrome with craniofacial dysplasia: clinical review and surgical management. Surg. Neurol. Int. 7, 165 (2016). · doi:10.4103/2152-7806.178567
  136. Boyce, A. M. et al. Association of hearing loss and otologic outcomes with fibrous dysplasia. JAMA Otolaryngol. Neck Surg. 144, 102 (2018). · doi:10.1001/jamaoto.2017.2407
  137. Akintoye, S. O. et al. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 91, 2960–2966 (2006). · doi:10.1210/jc.2005-2661
  138. Galland, F. et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J. Clin. Endocrinol. Metab. 91, 4957–4961 (2006). · DOI
  139. Carney, J. A., Gordon, H., Carpenter, P. C., Shenoy, B. V. & Go, V. L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine 64, 270–283 (1985). · DOI · Paper page
  140. Raff, S. B., Carney, J. A., Krugman, D., Doppman, J. L. & Stratakis, C. A. Prolactin secretion abnormalities in patients with the ‘syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). J. Pediatr. Endocrinol. Metab. 13, 373–379 (2000).
  141. Stergiopoulos, S. G. & Stratakis, C. A. Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease! FEBS Lett. 546, 59–64 (2003). · DOI
  142. Stergiopoulos, S. G., Abu-Asab, M. S., Tsokos, M. & Stratakis, C. A. Pituitary pathology in Carney complex patients. Pituitary 7, 73–82 (2004). · DOI
  143. Boikos, S. A. & Stratakis, C. A. Pituitary pathology in patients with Carney Complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary 9, 203–209 (2006). · DOI
  144. Pack, S. D. et al. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the ‘complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). J. Clin. Endocrinol. Metab. 85, 3860–3865 (2000).
  145. Pellegata, N. S. et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA 103, 15558–15563 (2006). · DOI · Paper page
  146. Belar, O., De La Hoz, C., Perez-Nanclares, G., Castano, L. & Gaztambide, S. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin. Endocrinol. 76, 719–724 (2011). · doi:10.1111/j.1365-2265.2011.04269.x
  147. Occhi, G. et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLOS Genet. 9, e1003350 (2013). · DOI
  148. Molatore, S. et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum. Mutat. 31, E1825–E1835 (2010). · doi:10.1002/humu.21354
  149. Georgitsi, M. et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92, 3321–3325 (2007). · DOI · Paper page
  150. Georgitsi, M. MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Pract. Res. Clin. Endocrinol. Metab. 24, 425–437 (2010). · doi:10.1016/j.beem.2010.01.001
  151. Tichomirowa, M. A. et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr. Relat. Cancer 19, 233–241 (2012). · doi:10.1530/erc-11-0362
  152. Sambugaro, S. et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region. Endocrine 49, 58–64 (2015). · doi:10.1007/s12020-015-0540-y
  153. Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85, 721–732 (1996). · DOI · Paper page
  154. Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85, 733–744 (1996). · DOI · Paper page
  155. Nakayama, K. et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707–720 (1996). · DOI · Paper page
  156. Xekouki, P. et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J. Clin. Endocrinol. Metab. 100, E710–E719 (2015). This paper provides an account of the emerging relationship of paraganglioma and phaeochromocytoma risk genes and pituitary tumours. · DOI · Paper page
  157. O’Toole, S. M., Dénes, J., Robledo, M., Stratakis, C. A. & Korbonits, M. 15 YEARS OF PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr. Relat. Cancer 22, T105–T122 (2015). · DOI
  158. Dénes, J. et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J. Clin. Endocrinol. Metab. 100, E531–E541 (2015). · DOI · Paper page
  159. Daly, A. F. et al. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocr. Relat. Cancer 25, L37–L42 (2018). · doi:10.1530/erc-18-0065
  160. Tudorancea, A. et al. Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy. Ann. Endocrinol. (Paris). 73, 37–42 (2012). · doi:10.1016/j.ando.2011.12.001
  161. Xekouki, P. et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J. Clin. Endocrinol. Metab. 97, E357–E366 (2011). · DOI · Paper page
  162. Cambiaso, P. et al. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma. Am. J. Med. Genet. A 173A, 2353–2358 (2017). · DOI
  163. Blanchard, G. et al. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur. J. Paediatr. Neurol. 20, 275–281 (2016). · doi:10.1016/j.ejpn.2015.12.002
  164. Cnossen, M. H. et al. Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100, 667–670 (1997). · DOI
  165. Listernick, R., Ferner, R. E., Liu, G. T. & Gutmann, D. H. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann. Neurol. 61, 189–198 (2007). · DOI · Paper page
  166. Sani, I. & Albanese, A. Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 87, 179–188 (2017). · doi:10.1159/000458525
  167. Segal, L., Darvish-Zargar, M., Dilenge, M.-E., Ortenberg, J. & Polomeno, R. C. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J. AAPOS 14, 155–158 (2010). · doi:10.1016/j.jaapos.2009.11.020
  168. Bruzzi, P., Sani, I. & Albanese, A. Reversible growth hormone excess in two girls with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 84, 414–422 (2015). · doi:10.1159/000440956
  169. Manski, T. J., Haworth, C. S., Duval-Arnould, B. J. & Rushing, E. J. Optic pathway glioma infiltrating into somatostatinergic pathways in a young boy with gigantism. Case report. J. Neurosurg. 81, 595–600 (1994). · doi:10.3171/jns.1994.81.4.0595
  170. Josefson, J. L., Listernick, R., Charrow, J. & Habiby, R. L. Growth hormone excess in children with optic pathway tumors is a transient phenomenon. Horm. Res. Paediatr. 86, 35–38 (2016). · doi:10.1159/000447326
  171. Melmed, S. et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009). · DOI · Paper page
  172. Katznelson, L. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly — 2011 update: executive summary. Endocr. Pr. 17 (Suppl. 4), 1–44 (2011).
  173. Ezzat, S. et al. Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin. Invest. Med. 29, 29–39 (2006).
  174. Hindmarsh, P. C., Pringle, P. J., Stanhope, R. & Brook, C. G. The effect of a continuous infusion of a somatostatin analogue (octreotide) for two years on growth hormone secretion and height prediction in tall children. Clin. Endocrinol. (Oxf.) 42, 509–515 (1995). · DOI
  175. Hindmarsh, P. C., Pringle, P. J., Di Silvio, L. & Brook, C. G. A preliminary report on the role of somatostatin analogue (SMS 201–995) in the management of children with tall stature. Clin. Endocrinol. (Oxf.) 32, 83–91 (1990). · doi:10.1111/j.1365-2265.1990.tb03753.x
  176. Goldenberg, N. et al. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J. Clin. Endocrinol. Metab. 93, 2953–2956 (2008). · doi:10.1210/jc.2007-2283
  177. Daniel, A., d’Emden, M. & Duncan, E. Pituitary gigantism treated successfully with the growth hormone receptor antagonist, pegvisomant. Intern. Med. J. 43, 345–347 (2013). · doi:10.1111/imj.12077
  178. Creo, A. L. & Lteif, A. N. Pituitary gigantism: a retrospective case series. J. Pediatr. Endocrinol. Metab. 29, 597–602 (2016).
  179. Maheshwari, H. G. et al. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J. Clin. Endocrinol. Metab. 85, 3409–3416 (2000).
  180. Müssig, K. et al. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. Exp. Clin. Endocrinol. Diabetes 115, 198–202 (2007). · doi:10.1055/s-2007-956172
  181. Rix, M., Laurberg, P., Hoejberg, A. S. & Brock-Jacobsen, B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur. J. Endocrinol. 153, 195–201 (2005). · doi:10.1530/eje.1.01956
  182. Mangupli, R. et al. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening. Pituitary 19, 507–514 (2016). · doi:10.1007/s11102-016-0732-3
  183. Franck, S. E. et al. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. Eur. J. Endocrinol. 176, 421–430 (2017). · doi:10.1530/eje-16-0956
  184. Neggers, S. J. & van der Lely, A. J. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm. IGF Res. 21, 129–133 (2011). · doi:10.1016/j.ghir.2011.03.004
  185. Trainer, P. J. et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000). · DOI · Paper page
  186. Bernabeu, I. et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16, 101–108 (2013). · DOI
  187. Personnier, C. et al. Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm. Res. Paediatr. 75, 392–402 (2011). · DOI
  188. Daly, A. et al. X-Linked acro-gigantism (X-LAG) syndrome: two new cases with long-term follow-up [abstract]. 4th ENEA Workshop https://orbi.uliege.be/handle/2268/189337 (2015).
  189. Petrossians, P. et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61–66 (2005). · doi:10.1530/eje.1.01824
  190. Saldarriaga, C. et al. Postoperative diabetes insipidus and hyponatremia in children after transsphenoidal surgery for adrenocorticotropin hormone and growth hormone secreting adenomas. J. Pediatr. 195, 169–174 (2018). · DOI
  191. Hindmarsh, P. C. Long-term follow-up after bilateral percutaneous epiphysiodesis around the knee to reduce excessive predicted final height. Arch. Dis. Child. 103, 207–208 (2018). This article presents an expert assessment of the challenges of epiphysiodesis and outcomes in tall stature. · doi:10.1136/archdischild-2017-313932
  192. Edouard, T. What treatment for a child with tall stature? Ann. Endocrinol. (Paris) 78, 104–105 (2017). · doi:10.1016/j.ando.2017.04.007
  193. Odink, R. J. et al. Reduction of excessive height in boys by bilateral percutaneous epiphysiodesis around the knee. Eur. J. Pediatr. 165, 50–54 (2006). · doi:10.1007/s00431-005-1722-z
  194. Benyi, E. et al. Efficacy and safety of percutaneous epiphysiodesis operation around the knee to reduce adult height in extremely tall adolescent girls and boys. Int. J. Pediatr. Endocrinol. 2010, 740629 (2010). · doi:10.1186/1687-9856-2010-740629
  195. Goedegebuure, W. J. et al. Long-term follow-up after bilateral percutaneous epiphysiodesis around the knee to reduce excessive predicted final height. Arch. Dis. Child. 103, 219–223 (2018). · doi:10.1136/archdischild-2017-314585.26

Cited by

See all 79

Metadata

Authors
Beckers, A., Petrossians, P., Hanson, J., & Daly, A. F.
Venue
Nature Reviews Endocrinology
Published
2018-10-25
Volume
14
Issue
12
Pages
705-720
ISSN
  • 1759-5029
  • 1759-5037
Cited by
79
References
5
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The causes and consequences of pituitary gigantism. https://app.cochat.ai/papers/10.1038/s41574-018-0114-1
The paper
Beckers, A., Petrossians, P., Hanson, J., & Daly, A. F. (2018). The causes and consequences of pituitary gigantism. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-018-0114-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.